Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04866953 · ClinicalTrials.gov registry record
UltraMTP in Adult Trauma Patients Undergoing Surgery Within 24 Hours: Effects on Mortality and Clinical Outcomes
A clinical trial, sponsored by University of Southern California.
- Completed
- Registry status
- 3,000
- Enrollment target
NCT04866953: Completed study, sponsored by University of Southern California.
NCT04866953 is a clinical trial that has completed, run by University of Southern California. The registered enrollment target is 3,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04866953 has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 3,000 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of ultraMTP (\>/=30 units pRBC within 24 hours) in trauma patients on mortality and secondary outcomes. The aim is to determine if there is a set number of pRBC units transfused in adult trauma patients undergoing surgery within 24 hours, after which mortality is inevitable and further transfusions are futile.
Primary Outcome
24-hour mortality (yes/no)
Interventions
- OTHER Blood transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2021-08-15 |
| Est. Completion | 2023-12-31 |
What the finished NCT04866953 record still lists
NCT04866953 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Blood transfusion is the first listed.
NCT04866953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04866953 about?
NCT04866953 is a clinical study titled "UltraMTP in Adult Trauma Patients Undergoing Surgery Within 24 Hours: Effects on Mortality and Clinical Outcomes". The purpose of this study is to determine the effects of ultraMTP (\>/=30 units pRBC within 24 hours) in trauma patients on mortality and secondary outcomes. The aim is to determine if there is a set number of pRBC units transfused in adult trauma patients undergoing surgery within 24 hours, after w...
What is the current status of trial NCT04866953?
This trial is currently completed. The enrollment target is 3,000 participants. The study started on 2021-08-15. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04866953?
The interventions under investigation include: Blood transfusion (OTHER).
Who is sponsoring clinical trial NCT04866953?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI